Epigenetics lab for multiple myeloma
Core 3 - Epigenomics Core
This project looks at how DNA packaging and chemical marks in multiple myeloma cells from patients might point to new targets for treatment.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11179332 on NIH RePORTER |
What this research studies
Researchers will analyze tumor cells taken from patients in past and ongoing myeloma clinical trials using methods that read DNA accessibility (ATAC-seq), protein–DNA interactions (ChIP-seq), and single-cell multi-omics to profile individual cells. Tumor cells will be isolated using established procedures so the epigenetic measurements reflect the cancer cells rather than surrounding tissue. The core can work with very small cell numbers and will adapt methods as needed to answer specific questions about gene regulation. Results will be combined with data from other project teams to create detailed maps of chromatin and epigenetic changes in myeloma.
Who could benefit from this research
Good fit: Ideal candidates are people with multiple myeloma who can provide tumor samples, including those newly diagnosed or with relapsed disease and patients enrolled at participating clinical sites or trials.
Not a fit: People without multiple myeloma or those who cannot provide tumor samples are unlikely to receive direct benefit from this core's activities.
Why it matters
Potential benefit: If successful, this work could uncover molecular markers or targets that help guide new therapies or predict relapse in multiple myeloma.
How similar studies have performed: Techniques like ATAC-seq, low-input ChIP-seq, and single-cell multi-omics have successfully mapped chromatin changes in cancers, though translating those maps into new treatments is still in progress.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Epstein, Charles B — Dana-Farber Cancer Inst
- Study coordinator: Epstein, Charles B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.